Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03965897 · ClinicalTrials.gov registry record · Phase 2

Preventing Persistent Post-Surgical Pain and Dysfunction

A Phase 2 study of Depression and Pain, sponsored by Barbara A Rakel.

Completed
Registry status
Phase 2
Development phase
487
Enrollment target
1
Study location

NCT03965897: Completed Phase 2 study of Depression and Pain, sponsored by Barbara A Rakel.

NCT03965897 is a Phase 2 study of Depression and Pain that has completed, run by Barbara A Rakel. The registered enrollment target is 487 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03965897, a Phase 2 study of Depression and Pain, has completed, sponsored by Barbara A Rakel.

COMPLETED
Registry status
Phase 2
Development phase
487 participants
Enrollment target
1
Study location

Study Summary

Primary Aim: To examine the superior efficacy of ACT versus Attention Control (AC) on postoperative pain intensity and functioning in at-risk Veterans undergoing TKA. Changes in pain intensity and functioning from baseline to 6 weeks, 3 months and 6 months post-TKA will be compared. Level of pain intensity will be measured using the BPI Pain Severity Subscale and level of functioning will be measured using the KOOS Activities of Daily Living and Quality Of Life Subscales. Secondary Aims: A) To examine the superior efficacy of ACT versus AC on the severity of anxiety and depressive symptoms and improvements in coping skills. Changes from baseline to 6 weeks, 3 months and 6 months post-TKA will be compared. Anxiety and depressive symptoms will be measured with the Hamilton Rating Scales (Ham-A and Ham-D, respectively). Coping skills (i.e. Pain Acceptance and Engagement in Values-Based Behavior) will be measured with the Chronic Pain Acceptance Questionnaire and the Chronic Pain Values Inventory. B) To evaluate whether decreases in distress-based symptoms and increases in coping skills mediate changes in pain and functioning at 6 months in Veterans receiving ACT. Changes in anxiety symptoms, depressive symptoms, pain acceptance and engagement in values-based behavior from baseline to 6 weeks and 3 months will be used as potential mediators for changes in pain and functioning at 6 months. Exploratory Aim: Describe the pharmacological and non-pharmacological strategies Veterans are using to manage pain and their perceived helpfulness. This will provide insights into the effects of the current opioid restrictions on pain management strategies. These strategies \& their perceived helpfulness will be assessed using the Pain Management Strategies Survey at baseline, 6 weeks, 3, and 6 months.

Primary Outcome

Pain will be measured using the Brief Pain Inventory (BPI) Scale: 0-10, with higher scores meaning worse pain

Interventions

  • BEHAVIORAL Acceptance and Committment Therapy (ACT)
  • OTHER Attention Control (AC)

Study Locations (1)

Iowa

  • Iowa City VAMC - Iowa City

Trial Details

FieldValue
Enrollment Target 487 participants
Start Date 2019-07-29
Est. Completion 2024-01-30
Phase Phase 2
Barbara A Rakel

3 total trials

What the finished NCT03965897 record still lists

NCT03965897 is an interventional study that assigns participants to a tested intervention. The registered 487 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (38% lower).

The record links to 6 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Acceptance and Committment Therapy (ACT) is the first listed.

NCT03965897 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT03965897 about?

NCT03965897 is a clinical study titled "Preventing Persistent Post-Surgical Pain and Dysfunction". Primary Aim: To examine the superior efficacy of ACT versus Attention Control (AC) on postoperative pain intensity and functioning in at-risk Veterans undergoing TKA. Changes in pain intensity and functioning from baseline to 6 weeks, 3 months and 6 months post-TKA will be compared. Level of pain in...

What is the current status of trial NCT03965897?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 487 participants. The study started on 2019-07-29. Estimated completion is 2024-01-30.

What conditions does trial NCT03965897 study?

This clinical trial studies the following conditions: Depression, Pain, Anxiety, Arthroplasty, Replacement, Knee, Veterans.

What interventions are being tested in trial NCT03965897?

The interventions under investigation include: Acceptance and Committment Therapy (ACT) (BEHAVIORAL), Attention Control (AC) (OTHER).

Who is sponsoring clinical trial NCT03965897?

This trial is sponsored by Barbara A Rakel, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03965897 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03965897's enrollment target sits among peer trials

487 91st of 679 higher than 589 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06948435 · 487 participants · Phase 3

    A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

  • NCT06952530 · 487 participants · Phase 3

    A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

  • NCT05154669 · 488 participants · Phase 3

    Integrating Financial Coaching and Smoking Cessation Coaching

  • NCT06532877 · 488 participants · NA

    Telephone Support in Advanced Gastrointestinal Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03965897, the US trial registry maintained by the National Library of Medicine. NCT03965897 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.